NCT06238284尚未招募不适用
HER2 Expression in Gynecological Malignant Tumors in Chongqing Area of China
Chongqing University Cancer Hospital0 个研究点目标入组 300 人开始时间: 2024年1月26日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 300
- 主要终点
- HER2 status
研究概览
简要总结
This study aims to retrospectively analyze the HER2 expression of gynecological malignant tumors in Chongqing by immunohistochemical detection, and explore the correlation between HER2 level, therapy response and prognosis based on patient clinical information.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Patients with primary gynecological malignant tumor confirmed by histopathology
- •Women aged 18-75
- •The expected survival time is greater than 12 weeks
- •KPS > 60, ECOG score is 0-2
- •All subjects voluntarily joined this study with informed consents, and had good compliance of follow-up
排除标准
- •Pregnant and lactating women
- •Suffering from other malignant tumors in the past 5 years
- •Patients who are not suitable for this study according to the investigator's judgment
结局指标
主要结局
HER2 status
时间窗: from 2023.07 to 2024.05
HER2 exprssion level evaluated by pathologists
次要结局
未报告次要终点
研究者
相似试验
招募中
不适用
HER2 Expression of CTC to Predict Response in HER2-low Advanced Breast Cancer Patients Treated With ADCBreast CancerNCT05834699Beijing 302 Hospital50
招募中
不适用
HER2 Expression of CTC to Predict Response in HER2-positive Advanced Breast Cancer Patients Treated With ADCBreast CancerNCT05834686Beijing 302 Hospital50
已完成
不适用
Research on HER2 expression in metastatic colorectal cancerColorectal cancerJPRN-UMIN000018786Japan Clinical Cancer Research Organization100
Unknown
不适用
The Clinical Study of Assessing HER-2 Expression in Gastric Cancer With Extra Tumor Tissue Paraffin Blocks Using ImmunohistochemistryGastric Cancer Surgical Specimens,18-80 Years Old, at Least Two Tumor Tissue BlocksNCT02843412Shanghai Zhongshan Hospital2,000
已完成
2 期
Clinical Value of 89Zr-trastuzumab PETMetastatic Breast CancerNCT01832051University Medical Center Groningen20